手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| ループス活動性の医師による総合評価 (PGA)× | 全身性エリテマトーデス疾患活動性指数 2000 (SLEDAI-2K)× | |
|---|---|---|
| 分野 | リウマチ学 | リウマチ学 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 1992 | 2002 |
| 提唱者≠ | Bombardier et al. | Gladman et al. |
| 種類 | Clinician-rated | Clinician-rated |
| 原典≠ | Petri M. Thermodynamic instability in the pathogenesis of lupus nephritis. Nat Rev Rheum. 2016;12(11):635-642. link ↗ | Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291. link ↗ |
| 別名 | Physician Global Assessment, PGA-Lupus, Clinician Global Assessment-SLE | SLEDAI, SLEDAI-2K, SLE Disease Activity Index |
| 関連 | 3 | 3 |
| 概要≠ | The Physician Global Assessment (PGA) is a clinician-rated, single-item measure of overall systemic lupus erythematosus (SLE) disease activity on a visual analogue scale (0–10). Used alongside structured indices like SLEDAI, PGA captures the clinician's integrated judgment of SLE severity, synthesising clinical examination, serology, imaging, and organ-specific findings into a holistic activity score. PGA is simple, practical, and widely used in SLE research and clinical practice as a complementary measure that reflects experienced clinician assessment of disease state. | The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease. |
| ScholarGateデータセット ↗ |
|
|